Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Not Recruiting

Trial ID: NCT02375204


This randomized phase III trial studies how well standard-dose combination chemotherapy works compared to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not yet known whether high-dose combination chemotherapy and stem cell transplant are more effective than standard-dose combination chemotherapy in treating patients with refractory or relapsed germ cell tumors.

Official Title

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Stanford Investigator(s)

Heather Wakelee
Heather Wakelee

Winston Chen and Phyllis Huang Professor

Alice C. Fan
Alice C. Fan

Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology

Andrew Rezvani, M.D.
Andrew Rezvani, M.D.

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Lori Muffly
Lori Muffly

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Wen-Kai Weng, MD, PhD
Wen-Kai Weng, MD, PhD

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology

Robert Lowsky
Robert Lowsky

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Laura Johnston
Laura Johnston

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Robert Negrin
Robert Negrin

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Sandy Srinivas
Sandy Srinivas

Professor of Medicine (Oncology) and, by courtesy, of Urology

Harcharan Gill
Harcharan Gill

Kathryn Simmons Stamey Professor, Emeritus


1. Documentation of Disease

      - Histologic Documentation: Confirmation of GCT histology (both seminoma and
      nonseminoma) on pathologic review at the center of enrollment.

      - Tumor may have originated in any primary site. NOTE: In rare circumstances,
      patients will be allowed to enroll even if a pathologic diagnosis may not have
      been established.

      - This would require a clinical situation consistent with the diagnosis of GCT
      (testicular, peritoneal, retroperitoneal or mediastinal mass, elevated tumor
      marker levels {HCG ≥ 500; AFP ≥ 500} and typical pattern of metastases)

   2. Evidence of Disease

      - Must have evidence of progressive or recurrent GCT (measurable or non-measurable)
      following one line of cisplatin-based chemotherapy, defined as meeting at least
      one of the following criteria:

         - Tumor biopsy of new or growing or unresectable lesions demonstrating viable
         non-teratomatous GCT (enrollment on this study for adjuvant treatment after
         macroscopically complete resection of viable GCT is not allowed). In the
         event of an incomplete gross resection where viable GCT is found, patients
         will be considered eligible for the study.

         - Consecutive elevated serum tumor markers (HCG or AFP) that are increasing.
         Increase of an elevated LDH alone does not constitute progressive disease.

         - Development of new or enlarging lesions in the setting of persistently
         elevated HCG or AFP, even if the HCG and AFP are not continuing to increase.

   3. Prior Treatment

      - Must have received 3-6 cycles of cisplatin-based chemotherapy as part of
      first-line (initial) chemotherapy.

         - Prior POMBACE, CBOP-BEP, or GAMEC are allowed.

         - Note: For patients requiring immediate treatment, 1 cycle of
         conventional-dose salvage chemotherapy is allowed. Therefore, these patients
         may have received 7 prior cycles of chemotherapy. 6 cycles as part of
         first-line chemotherapy and 1 cycle of salvage conventional chemotherapy.

      - No more than one prior line of chemotherapy for GCT (other than the 1 cycle of
      salvage chemotherapy as defined in the protocol)

         - Definition of one line of chemotherapy: One line of therapy can in some
         cases consist of 2 different cisplatin-based treatment combinations,
         provided there is no disease progression between these two regimens.

         - Prior treatment with carboplatin as adjuvant therapy is allowed, provided
         patients meet other eligibility criteria (e.g., the patient has also
         received 3-4 cycles of cisplatin-based chemotherapy).

         - Prior treatment with 1-2 cycles of BEP or EP as adjuvant chemotherapy for
         early stage GCT is allowed, provided the patient also received 3-4 cycles of
         BEP or EP again at relapse. Patients treated with 3-4 cycles of VIP at
         relapse following 1-2 cycles of BEP/EP are not eligible as this would be
         considered more than 1 line of prior therapy.

      - No prior treatment with high-dose chemotherapy (defined as treatment utilizing
      stem cell rescue)

      - No prior treatment with TIP with the exception when given as a bridge to
      treatment on protocol for patients with rapidly progressive disease who cannot
      wait to complete the eligibility screening process. Only one cycle is allowed.

      - No concurrent treatment with other cytotoxic drugs or targeted therapies.

      - No radiation therapy (other than to the brain) within 14 days of day 1 of
      protocol chemotherapy except radiation to brain metastases, which must be
      completed 7 days prior to start of chemotherapy.

      - No previous chemotherapy within 17 days prior to enrollment. A minimum of three
      weeks after the last day of the start of the previous chemotherapy regimen before
      the first day of chemotherapy on study protocol.

      - Must have adequate recovery from prior surgery (eg, healed scar, resumption of

   4. Age ≥ 14 years (≥ 18 years in Germany)

   5. ECOG Performance Status 0 to 2

   6. Male gender

   7. Required Initial Laboratory Values:

      - Absolute Neutrophil Count (ANC) ≥ 1,500/mm^3

      - Platelet Count ≥ 100,000/mm^3

      - Calculated creatinine clearance ≥ 50 mL/min

      - Bilirubin ≤ 2.0 x upper limits of normal (ULN)

      - AST/ALT ≤ 2.5 x upper limits of normal (ULN)

   8. No concurrent malignancy other than non-melanoma skin cancer, superficial noninvasive
   (pTa or pTis) TCC of the bladder, contralateral GCT, or intratubular germ cell
   neoplasia. Patients with a prior malignancy, but at least 2 years since any evidence
   of disease are allowed.

   9. Negative Serology (antibody test) for the following infectious diseases:

      - Human Immunodeficiency Virus (HIV) type 1 and 2

      - Human T-cell Leukemia Virus (HTLV) type 1 and 2 (mandatory in US but optional in
      Canada and Europe)

      - Hepatitis B surface antigen

      - Hepatitis C antibody

10. No late relapse with completely surgically resectable disease. Patients with late
   relapses (defined as relapse ≥ 2 years from the date of completion of the last
   chemotherapy regimen) whose disease is completely surgically resectable are not
   eligible. Patients with late relapses who have unresectable disease are eligible.

11. No large (≥ 2 cm) hemorrhagic or symptomatic brain metastases until local treatment
   has been administered (radiation therapy or surgery). Treatment may begin ≥ 7 days
   after completion of local treatment. Patients with small (< 2 cm) and asymptomatic
   brain metastases are allowed and may be treated with radiation therapy and/or surgery
   concurrently with Arm A or cycles 1 and 2 of Arm B if deemed medically indicated.

   Radiation therapy should not be given concurrently with high-dose carboplatin or

12. No secondary somatic malignancy arising from teratoma (e.g., teratoma with malignant
   transformation) when it is actively part of the disease recurrence or progression.


drug: paclitaxel

drug: ifosfamide

drug: cisplatin

drug: pegylated G-CSF

drug: G-CSF

drug: carboplatin

drug: etoposide phosphate

procedure: stem cell reinfusion

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sneha Mohile

New Trial Alerts

Receive email alerts when trials open to patients.